Since the start of the pandemic, analyst forecasts for 2020 product sales have dropped by $4.9 billion for the top 15 companies, EvaluatePharma found. Merck is expected to lose the most sales this year due to the pandemic, with a decrease of about $1.3 billion.
How the total 2020 sales forecasts changed between March and June for the top 15 pharma companies:
- GlaxoSmithKline: +$650 million
- Eli Lilly: +$243 million
- Gilead Sciences: +$77 million
- Takeda: +$56 million
- Johnson & Johnson: -$7 million
- Bristol-Myers Squibb: -$119 million
- Amgen: -$285 million
- AstraZeneca: -$330 million
- Novartis: -$378 million
- AbbVie: -$512 million
- Sanofi: -$592 million
- Roche: -$619 million
- Bayer: -$675 million
- Pfizer: -$1.2 billion
- Merck: -$1.3 billion
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
CVS fined for understaffing, prescription errors in Oklahoma
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.